More than 450 million Chinese—one in three people in the world’s most populous country—suffer from nearsightedness, according to statistics released by China’s National Health Commission in June. Sixty years ago, 10%-20% of the Chinese population was short-sighted. Today, one third—including a startling... Read More
In May, the Chinese government published its first national list of rare diseases, a welcome development for foreign pharmaceutical companies eager to market treatments for their products there. The list of 121 diseases identified as rare was published by five Chinese government... Read More
Chronic obstructive pulmonary disease (COPD) is more prevalent in China than anywhere else in the world, afflicting more than 8.6% of adults, according to a new study by researchers at Tulane University. Almost 100 million people in China suffer from the group... Read More
Seeking to bolster its artificial intelligence (AI) industry in the face of foreign competition, South Korea has announced plans to invest $2 billion over three years in the development of thinking computer systems. Among the research priorities outlined by Korea’s science ministry... Read More
China’s Center for Medical Device Evaluation (CMDE) has issued a new draft guidance for obtaining approval of 3D-printed medical devices, as the nation’s regulatory authorities focus new attention on the fast-developing field of 3D printing technology. The guidance, proposed by the agency... Read More
An alarming jump in mental illness in some of Asia’s fastest developing countries has made the region the third largest market in the world for mental health therapeutics, even as social stigma and lack of professional services leave a majority of the... Read More
China’s in vitro diagnostics (IVD) market is growing at an annual rate of 13.2% and is projected to reach a valuation of $5.9 billion by 2022. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest... Read More
This article was originally published on MedTech Intelligence. Driven largely by hepatitis in its various forms, liver disease has long been a fixture of life in China and Southeast Asia. Over the past three decades, public health programs in the region have... Read More
In March 2018, Chinese Premier Li Keqiang announced that China will reduce tariffs on imported cancer drugs to zero percent. The plan should give a boost to global drug makers such as AstraZeneca, Novartis, Pfizer, and Roche by making their treatments more... Read More
This article was originally published on MedTech Intelligence. Last year, Research and Markets released a report projecting that China’s in vitro diagnostics (IVD) market is likely to triple in size before 2022. This growth is driven by an aging population, a growing... Read More